Figure 3.

CD36 triggers blast migration. A, GO analysis of migration-related biological processes significantly enriched in the CD36 gene signature. B, Number of migrating shCtrl or shCD36 U937 cells in the lower chamber of the transwell assay (normalized to control; n = 5). C, As in B, but with CD36-blocking antibodies (FA6-152 or JC53.1; n = 4). D, Number of migrating cells in primary AML samples treated or not with CD36 blocking antibody (FA6-152; n = 7). E, Number of migrating shCtrl or shTSP1 U937 cells (normalized to control; n = 3). F, Number of migrating shCtrl or shCD36 U937 cells treated or not with TSP1-blocking antibody (A6.1; normalized to shCtrl; n = 5). G, Number of migrating U937 cells treated or not with recombinant TSP1 in the presence or not of CD36-blocking antibody (FA6-152; normalized to control; n = 3). H, As in D, but with TSP1-blocking antibody (A6.1; n = 5). I, Bioluminescence imaging of mice injected with the indicated AML cell line stably expressing a luciferase reporter from day 1 to day 64 after injection. J, Representative histologic section showing anti-human Ku-80 labeling of U937 AML blasts in the subcutaneous adipose tissue 17 days after xenograft. Positive brown nuclei highlight the infiltration of human blasts in murine adipose tissue either as dense infiltrate (top) or scattered isolated cells (bottom). Top scale bar, 50 μm; bottom, 10 μm. K, Percentage of viable OCIAML3 cells in the indicated tissues 14 days after orthotopic injection in the femur. L, Expression of CD36 [mean fluorescence intensity (MFI)] in viable OCIAML3 cells measured in the injected and contralateral femur and different organs of mice 14 days after orthotopic injection. Values are represented as mean ± SEM. B, C, and E, One sample t test. D and H, Paired t test. F and G, Ordinary one-way ANOVA with Tukey multiple comparisons test. L, Matched one-way ANOVA. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant.